Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LGVN
stocks logo

LGVN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2026Q1
110.33K
-81.7%
-0.257
-24.51%
416.67K
+9.36%
-0.240
-29.41%
Estimates Revision
The market is revising No Change the revenue expectations for Longeveron Inc. (LGVN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -20.09%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-20.09%
In Past 3 Month
Wall Street analysts forecast LGVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGVN is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast LGVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGVN is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.633
sliders
Low
3.00
Averages
3.50
High
4.00
Current: 0.633
sliders
Low
3.00
Averages
3.50
High
4.00
Roth Capital
Buy
downgrade
$10 -> $3
2025-08-15
Reason
Roth Capital
Price Target
$10 -> $3
2025-08-15
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Longeveron to $3 from $10 and keeps a Buy rating on the shares. The firm's price target cut reflects Q2 results and the dilutive equity financing earlier this week, though Longeveron remains an underappreciated firm despite its first-mover advantage in HLHS, or Hypoplastic Left Heart Syndrome, the analyst tells investors in a research note.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$10
2025-03-21
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$10
2025-03-21
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$10
2025-03-03
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$10
2025-03-03
Reiterates
Strong Buy
Reason
Roth MKM
Boobalan Pachaiyappan
Strong Buy
Initiates
$10
2024-12-05
Reason
Roth MKM
Boobalan Pachaiyappan
Price Target
$10
2024-12-05
Initiates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Longeveron Inc (LGVN.O) is -0.59, compared to its 5-year average forward P/E of -4.18. For a more detailed relative valuation and DCF analysis to assess Longeveron Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.18
Current PE
-0.59
Overvalued PE
-0.12
Undervalued PE
-8.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.14
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.83
Undervalued EV/EBITDA
-11.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
74.80
Current PS
0.00
Overvalued PS
159.97
Undervalued PS
-10.37
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 1320.29% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 1320.29% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

LGVN News & Events

Events Timeline

(ET)
2025-12-02
09:30:00
Longeveron Secures Canadian Patent for Laromestrocel Until 2037
select
2025-12-01 (ET)
2025-12-01
12:10:00
Longeveron Presents Alzheimer's Treatment Study Results at Clinical Trials Conference
select
2025-11-12 (ET)
2025-11-12
09:06:03
Longeveron Receives U.S. Patent for MSC Administration Methods
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-03Newsfilter
Longeveron Executives to Speak at CVCT Forum on Cell Therapy Innovations
  • Executive Participation: Longeveron's Chief Science Officer Dr. Joshua Hare and Chief Medical Officer Dr. Nataliya Agafonova will participate in multiple panel discussions at the Global Cardiovascular Clinical Trialists Forum from December 8-10, 2025, aimed at promoting evidence generation and global impact in cardiovascular clinical trials.
  • Cell Therapy Innovations: Dr. Hare will discuss the importance of cell delivery routes, particularly the potential of intravenous delivery of cells/cell products, emphasizing the application of cell therapy in heart failure treatment, which could introduce new therapeutic strategies in the field.
  • Multi-Stakeholder Discussions: Dr. Agafonova will engage in the CVCT multi-stakeholder think tank debate, fostering collaboration and innovation among experts from various fields to accelerate the development of cell therapies.
  • Product Development Progress: Longeveron's Lomecel-B® cell therapy has received five significant FDA designations, including Orphan Drug and Fast Track designations, highlighting its potential and market value in addressing rare diseases.
[object Object]
Preview
1.0
12-03Globenewswire
Longeveron Executives to Speak at Global CVCT Forum on Cell Therapy Innovations
  • Executive Participation: Longeveron's Chief Science Officer Dr. Joshua Hare and Chief Medical Officer Dr. Nataliya Agafonova will participate in multiple panel discussions at the Global CVCT Forum from December 8-10, 2025, in Washington, D.C., aiming to enhance evidence generation and global impact in cardiovascular clinical trials.
  • Cell Therapy Insights: Dr. Hare will discuss the importance of cell delivery routes and their application in heart failure trials, emphasizing the need for innovation in cell therapy to elevate clinical evidence levels, which could significantly advance the field.
  • Stakeholder Debate: Dr. Agafonova will engage in the CVCT multi-stakeholder think tank debate, aiming to gather diverse perspectives to accelerate innovation and development in cardiovascular disease treatments, fostering collaboration in clinical research.
  • Product Development Milestones: Longeveron's Lomecel-B® cell therapy has received five critical FDA designations, including Orphan Drug and Fast Track designations, highlighting its potential in addressing rare diseases and aging-related conditions.
[object Object]
Preview
3.5
12-02Newsfilter
Longeveron Secures Canadian Patent for Aging-Related Frailty Treatment
  • Patent Grant: Longeveron has secured Canadian Patent No. 3043594, covering the use of its proprietary mesenchymal stem cells for treating aging-related frailty and non-ischemic dilated cardiomyopathy, with patent rights extending to 2037, thereby strengthening its market position in stem cell therapies.
  • Clinical Trial Results: Initial positive results from two clinical trials of laromestrocel in aging-related frailty have shown improvements in the six-minute walk test and physical functioning, indicating its potential to enhance health outcomes for elderly patients.
  • Market Demand: Aging-related frailty, characterized by weakness, low physical activity, and unintentional weight loss, currently lacks effective treatments, and the development of laromestrocel is poised to address this unmet medical need, driving future growth for the company.
  • Multiple Mechanisms: As a living cell product, laromestrocel exhibits multiple potential mechanisms including anti-inflammatory and pro-vascular regenerative effects, suggesting broad applicability across various rare and aging-related diseases, further enhancing the company's R&D value.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Longeveron Inc (LGVN) stock price today?

The current price of LGVN is 0.6327 USD — it has decreased -0.63 % in the last trading day.

arrow icon

What is Longeveron Inc (LGVN)'s business?

Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.

arrow icon

What is the price predicton of LGVN Stock?

Wall Street analysts forecast LGVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGVN is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Longeveron Inc (LGVN)'s revenue for the last quarter?

Longeveron Inc revenue for the last quarter amounts to 137.00K USD, decreased -82.28 % YoY.

arrow icon

What is Longeveron Inc (LGVN)'s earnings per share (EPS) for the last quarter?

Longeveron Inc. EPS for the last quarter amounts to -0.39 USD, increased 14.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for Longeveron Inc (LGVN)'s fundamentals?

The market is revising No Change the revenue expectations for Longeveron Inc. (LGVN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -20.09%.
arrow icon

How many employees does Longeveron Inc (LGVN). have?

Longeveron Inc (LGVN) has 25 emplpoyees as of December 05 2025.

arrow icon

What is Longeveron Inc (LGVN) market cap?

Today LGVN has the market capitalization of 13.50M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free